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ABSTRACT
Background. Melanoma of unknown primary site (MUP)
is not a completely understood entity with nodal metastases
as the most common first clinical manifestation. The aim of
this multicentric study was to assess frequency and type of
oncogenic BRAF/NRAS/KIT mutations in MUP with clin-
ically detected nodal metastases in relation to
clinicopathologic features and outcome.
Materials and Methods. We analyzed series of 103 MUP
patients (period: 1992–2010) after therapeutic lymphade-
nectomy (LND): 40 axillary, 47 groin, 16 cervical, none
treated with BRAF inhibitors. We performed molecular
characterization of BRAF/NRAS/KIT mutational status in
nodal metastases using direct sequencing of respective
coding sequences. Median follow-up time was 53 months.
Results. BRAF mutations were detected in 55 cases
(53 %) (51 V600E, 93 %; 4 others, 7 %), and mutually
exclusive NRAS mutations were found in 14 cases (14 %)
(7 p.Q61R, 4 p.Q61K, 2 p.Q61H, 1 p.Q13R). We have not
detected any mutations in KIT. The 5-year overall survival
(OS) was 34 %; median was 24 months. We have not
found significant correlation between mutational status
(BRAF/NRAS) and OS; however, for BRAF or NRAS
mutated melanomas we observed significantly shorter dis-
ease-free survival (DFS) when compared with wild-type
melanoma patients (p = .04; 5-year DFS, 18 vs 19 vs
31 %, respectively). The most important factor influencing
OS was number of metastatic lymph nodes [1 (p = .03).
Conclusions. Our large study on molecular characteriza-
tion of MUP with nodal metastases showed that MUPs had
molecular features similar to sporadic non-chronic-sun-
damaged melanomas. BRAF/NRAS mutational status had
negative impact on DFS in this group of patients. These
observations might have potential implication for molec-
ular-targeted therapy in MUPs.
Metastatic involvement of lymph nodes is the most
common clinical manifestation of melanoma of unknown
primary site (MUP) and accounts for *3.2 % of all mel-
anoma cases, ranging from 1 to 15 % of all melanomas
with clinically detectable synchronous lymph nodes
involvement.1–7 Currently, according to the American Joint
Committee on Cancer (AJCC) guidelines, presentation of
initial metastases in the lymph nodes should be presumed
to be regional and staged accordingly (stage III instead of
stage IV), if no other site of metastases is discovered during
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screening process.8 We hypothesize, the pathogenesis and
molecular characteristics of MUP should be similar to
melanomas with nodal metastases from known primary
site.
It is now becoming clear that melanoma is not a
homogeneous disease, but rather a group of neoplasms
caused by different genetic changes and driven by different
mechanisms. Patterns of known genetic changes differ
significantly based on location of primary lesion and clin-
ical melanoma subtype. Products of genes most commonly
alternated in melanoma arising from the skin without
chronic sun damage (NCSD, non-chronic sun damaged) are
clustered in mitogen activated protein kinase (MAPK)
pathway.9–11 In a majority of cases, the hyperactivation of
MAPK pathway is caused by acquisition of oncogenic
mutation in BRAF or NRAS genes. BRAF mutations are the
most frequent changes in melanoma, and they comprise
40–70 % of cases depending on melanoma type.12–14 More
than 50 distinct mutations of BRAF gene were reported;
*90 % of them are due to a single nucleotide substitution
T1799A at codon position 600 in exon 15 (p.V600E)
leading to 500-fold increase in the protein activity. The
second most frequent mutation is p.V600K, and it is less
powerful as kinase activity increases. The important role of
BRAF alternations in melanoma development is proven;
however, the mutation itself is not sufficient for malignant
transformation, and BRAF mutations also occur with high
frequency in benign nevi.15
The frequency of NRAS mutation in melanoma of
cutaneous origin varies between 15 and 30 %.16 The
majority of changes in this gene affect codon 61 (exon 2) as
well as, to a lesser extent, codons 12 and 13 (exon 1).
Similarly to BRAF, the NRAS mutations role in tumori-
genesis is proven; however again, alone they are not
sufficient to cause malignant transformation. BRAF and
NRAS mutations are mutually exclusive, which suggests
functional redundancy in primary tumors. KIT alterations
are rare and found mainly in melanomas on chronically
sun-damaged skin, in acral-lentiginous or mucosal type.9
The prognostic role of alternations in BRAF and NRAS
genes is not yet determined. Some reports imply associa-
tion of BRAF/NRAS mutations and poorer prognosis in the
metastatic setting. However, differences in disease-free
survival (DFS) and overall survival (OS) according to
BRAF/NRAS mutational status are not seen, when calcu-
lated from primary tumor diagnosis.11,17,18 Also data on
survival in stage III melanoma patients according to NRAS
mutations are not unanimous.18,19 Mutations in both genes
are validated targets for molecular-targeted therapies in
melanoma (BRAF inhibitors vemurafenib and dabrafenib
for BRAF mutants and MEK inhibitor trametinib for
genotype containing any of the 2 genes altered).20–22
However, the molecular background of MUP, its linkage to
clinical data, and differences from melanoma of known
primary site are not fully understood, although they have
been explored in recent series.23,24
In the current study we analyzed frequency and type of
oncogenic mutations in known oncogenes (BRAF, NRAS,
and KIT) involved in melanoma development in large
contemporary series of MUP patients with long follow-up,
and we correlated these outputs with disease clinical fea-
tures and outcome. It may provide insight into molecular
pathogenesis and characterization of this melanoma
subtype.
MATERIALS AND METHODS
Patients Characteristics
Patients were considered eligible for the study if they
had diagnosed clinical (palpable) nodal metastases of
MUP, available tumor tissue, and underwent radical lymph
node dissection (LND) at 1 of the centers participating in
the study [Cancer Centre and Institute of Oncology, War-
saw, Poland (CCIO); Cancer Institute Gustave Roussy,
Villejuif, France (IGR); Erasmus MC Cancer Institute,
Rotterdam, Netherlands (Erasmus MC), and Medical Uni-
versity of Lodz, Poland (MU)].
The group of patients with MUP and lymph node
metastases was defined as: metastases to the lymph nodes
as first site of metastases, confirmed clinically, cytologi-
cally/histologically, and immunohistochemically; the
absence of previous cutaneous tumors or melanomas of
unusual primary sites; no prior excisions or destruction of
skin lesions without a pathologic examination; and no other
detectable metastases at diagnosis, after a detailed checkup
that included computed tomography imaging (neck, chest,
and abdomen).
Radical LNDs were performed between January 1992
and November 2010.
For the final examination, 103 formalin-fixed, paraffin-
embedded tumor tissues from MUP lymph node metastases
were selected, after pathological confirmation (40 from
CCIO, 7 from IGR, 52 from Erasmus MC, and 4 from
MU). There was access to complete clinical data including
date of LDN, date of disease relapse, last follow-up, or
death for all patients.
Patient characteristics are summarized in Table 1. The
study was approved by the local Bio-Ethics Committee
according to Good Clinical Practice Guidelines.
The patients had not undergone any other preliminary
selection. Only patients who met with all the conditions
listed previously were enrolled in the study. All patients
were followed carefully with a median follow-up time of
53 months for survivors (range 6–140 months) with
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standard postoperative follow-up protocol (surveillance
recommended every 3 months for the first 2 years, every
4 months in year 3, every 6 months for years 4–5, and
annually thereafter). Patients were not treated with any
BRAF or MEK inhibitors.
Mutational Testing
A total of 103 paraffin blocks from lymph nodes
metastases were selected (1 per patient), with the sufficient
tumor load and best possible material quality, as described
previously.23 Samples were cut from the whole block
surface. Genomic DNA was isolated with the Sherlock AX
DNA kit (A&A Biotechnology, Gdynia, Poland) and
amplified in standard polymerase chain reaction conditions
with in-house designed primers for BRAF exons 11, 15,
NRAS exons 1, 2, and KIT exons 9, 11, 13, 17. Products
were bidirectly sequenced with the BigDye Terminator
Cycle Sequencing Kit and ABI Prism 3100 Genetic Ana-
lyzer (Applied Biosystems, Carlsbad, CA, USA). In order
to identify mutations, the sequences were aligned to the
BRAF (NM_004333.4), NRAS (NM_002524.4), and KIT
(NM_000222.2) GenBank references.
Statistical Analyses
All statistical analyses were performed using R 2.15.1
statistical software (R Core Team (2012); http://www.R-
project.org). Contingency tables were analyzed using the
Chi square test. The nonparametric Mann–Whitney U test
was applied for comparisons of 2 groups with non-normal
distribution.
For survival analyses, the Kaplan–Meier estimator was
used with log-rank tests for bivariate comparisons. OS time
for the assessment of prognostic value of clinical, patho-
logical, and molecular parameters was calculated from the
TABLE 1 Patient characteristics and comparison between BRAF-mutant and BRAF wild-type melanomas in stage III melanomas with unknown
primary site
N (%) 103 (100 %) BRAF mutants BRAF wild type
N (%) 48
p value BRAF ? versus -
N (%) 55
Age, median (years) 54.5 51.5 56.5 ns (p = .08)
Age groups (years) ns
0–40 21 (17.6) 13 (23.7) 9 (18.8)
[40–60 45 (47.2) 27 (49.0) 18 (37.5)
60 36 (35.2) 15 (27.3) 21 (43.7)
Gender ns
Female 47 (45.6) 25 (45.5) 22 (45.8)
Male 56 (54.4) 30 (54.5) 26 (54.2)
Center ns
CCIO Warsaw 40 (39) 25 (45) 15 (31)
Erasmus MS, Rotterdam 52 (50) 25 (45) 27 (56.5)
IGR, Paris 7 (7) 3 (6) 4 (8.5)
MU, Lodz 4 (4) 2 (4) 2 (4)
Lymph nodal basin ns
Axillary 40 (39) 25 (45) 15 (31)
Inguinal 47 (46) 23 (42) 24 (50)
Cervical 16 (15) 7 (13) 9 (19)
Number of metastatic nodes ns
1 37 (36) 18 (32) 19 (40)
2–3 20 (19) 12 (21) 8 (17)
C4 46 (45) 19 (34) 27 (58)
Median 3 3 3
Extracapsular extension of metastatic node
(data not available in 40 cases)
ns
Present 27 (43) 15 (38) 12 (50)
Absent 36 (57) 24 (62) 12 (50)
ns not significant statistically
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date of LND to the date of the most recent follow-up
(censored data) or death. DFS time was calculated from the
date of therapeutic lymphadenectomy to the date of the
most recent follow-up or disease recurrence.
The following clinical, pathological, and molecular
parameters were tested as potential factors affecting patient
survival: gender, age (B40 vs 40–60 vs [60 years), LND
localization (groin vs axillary vs cervical), number of
lymph nodes with metastases (1 vs 2–3 vs C4), presence of
extracapsular invasion in the involved lymph nodes, BRAF
status (BRAF mutated vs wild type), and NRAS status
(NRAS mutated vs wild type).
The differences were considered statistically significant
if the respective p values were \.05.
RESULTS
Mutational Status and Correlation
with Clinicopathological Features
BRAF mutations were detected in 55 of 103 cases
(53.4 %) of melanoma nodal metastases. Majority of
mutations (54 of 55) affected codon 600: 51 were p.V600E
(92.7 %), 2 were p.V600 K (3.6 %), and 1 was
p.V600_K601delinsE codon deletion (1.8 %). The only
mutation outside codon 600 was p.E586K. A total of 48
samples were wild type for BRAF exons 11 and 15.
The analysis of NRAS gene status revealed 14 mutated
cases, 13 mutations affected codon 61 (7 p.Q61R, 4
p.Q61K, 2 p.Q61H) and 1 affected codon 13 (p.Q13R).
NRAS gene was mutated in 13.7 % of all samples, 29 % of
BRAF-WT samples. Mutations in BRAF and NRAS were
mutually exclusive, and 34 samples harbored neither. No
KIT mutations were detected in analyzed cases.
All cases with weak (\30 % of BRAF/NRAS wild-type)
mutation sequence peak were resequenced, resulting in
complete confirmation of the results.
The presence of BRAF mutation had trended to correlate
only with younger age of patients, with borderline signifi-
cance (median, 51.5 vs 56.5 years for BRAF? vs BRAF-;
p = .08) (Table 1). We found no differences in patient
characteristics when analyzed according to NRAS muta-
tional status. There were no differences in terms of
mutation distribution between participating centers.
Treatment Outcomes
The 5-year OS and DFS rates were 34 % [95 % confi-
dence interval (95 % CI) 25–46 %] and 24 % (95 % CI
16–35 %), respectively; median OS and DFS were
24 months (95 % CI 18.2–36.2 months) and 9 months
(95 % CI 6–12 months). There were no significant differ-
ences in OS and DFS between patients with BRAF- or
NRAS-mutated melanoma and those with no mutation. The
5-year survival rates were 36.0 and 29.8 % for patients
with wild-type and mutated BRAF genotype (p = .27),
respectively; 33.9 and 26.0 % for patients with wild-type
and mutated NRAS genotype (p = .31), respectively.
Median OS for patients with BRAF mutation versus NRAS
mutation versus wild-type were: 21.9 versus 15.1 versus
43.3 months, respectively. The trend for patients with
acknowledged mutations to have worse OS has not reached
statistical significance (p = .16) (Fig. 1a).
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FIG. 1 Overall survival according to: a BRAF and NRAS mutational
status in melanomas with unknown primary site and nodal involve-
ment and b to number of nodes with metastases
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The only negative factor that influenced OS significantly
was the number of lymph nodes involved [1 (5-year OS
rates, 46.4 vs 21.4 vs 26.3 % for 1 vs 2–3 vs[3 metastatic
lymph nodes, respectively; p = .03) (Fig. 1b). There was
also a trend for poorer survival in patients with extracap-
sular extension of nodal metastases, but it did not reach
statistical significance (5-year OS rates, 47 vs 33.5 % for
absence and presence of extracapsular involvement,
respectively; p = .1).
The 5-year DFS rates were 28.5 and 18.3 % for
patients without and with BRAF mutation, respectively
(median DFS, 11.8 vs 5.6 months; p = .03), and 31.3,
18.3, and 19.4 % for patients without any mutation and
with gene alternations in BRAF and NRAS, respectively
(median, 31.5 vs 5.6 vs 8.3 months; p = .04) (Fig. 2).
Presence of BRAF/NRAS mutations was related to sig-
nificantly shorter DFS.
DISCUSSION
In this study, we analyzed the large and clinically
homogeneous group of lymph node metastases that were
the first clinical manifestation of advanced melanoma
without known primary origin. We have performed the
largest mutational analyses in MUP metastatic nodes
specimens and more comprehensive survival evaluation in
respect to BRAF/NRAS status than has been published to
date.23,24
Mutation distribution in the MUP study group was
similar to those observed in other groups with melanoma of
known primary site at stage III and IV and included 53 %
of BRAF mutants (with the p.V600E as the most prevalent
mutation) and 14 % of mutually exclusive NRAS
mutants.6,16,18,25–27 No KIT mutations were found.
Based on our mutational data we have shown that a
population of MUP patients have a similar distribution of
BRAF/NRAS alterations to the known primary melanoma
patients exposed to similar/identical environmental factors
(such as UV exposure, but not exclusively), confirming
data from other smaller published series.16,18,23,24,28 The
incidence of mutations is consistent with those already
observed for melanoma originating on skin without chronic
sun damage, which is the most common type in Central and
Western Europe.29 It implies common pathogenesis for
tumor growth of MUP and other skin melanoma types.
There is no unambiguous theory on MUP development
mechanism. Widely acceptable is the assumption of
spontaneous, immune-induced, complete regression of the
primary lesion preceding clinical metastases.30 In fact,
melanoma is the most common tumor to undergo partial,
severe regression, and such events are well documented in
primary cutaneous melanoma with frequency of 3–8 %.31
Based on our knowledge of melanoma biology and clinical
course, other explanations of MUP origins are also possible
and include manifestation as a synchronous, unrecognized
melanoma in multiple lesions or malignant transformation
of benign nevus cells de novo in a lymph nodes.
The outcomes of our study are especially interesting
when compared with reports conducted on different MUP
patient populations, where other types of melanoma are
dominant. Kong et al.32 reported KIT alternations in
13.7 % (including 7.8 % KIT mutations) in a large group of
Chinese MUP patients. This is interesting, since acral-
lentiginous type of melanoma with higher frequency of KIT
alternations is the more frequent in Asian patients. How-
ever, it could also allude to a proportion of unrecognized
mucosal melanomas.
Patients with melanoma of primary unknown site tend to
have a prognosis and natural history of disease that is
similar to, if not more favorable than, patients with the
same staging characteristics, from a known primary cuta-
neous melanoma.5–7,33–36 In our group of MUP patients,
survival rates are comparable to previously reported series
(5-year OS rates ranged between 28.6 and 75.6 %) as well
as series of stage III patients with macrometastases used for
validation of AJCC staging system.7,33 It seems that our
multicenter group of MUP patients with nodal involvement
have outcomes not better than patients with detectable
primary tumor according to AJCC database. It implies that
they may derive from undetectable primary lesions in the
past that gave nodal metastases with lead time bias.
0
0
20
40
60
80
10
0
20
BRAF mutants
Wild-type
NRAS mutants
40
P=0.04
31.3%
19.4%
18.3%
60
Time (months)
Su
rv
iv
al
 [%
]
80 100 120
FIG. 2 Disease-free survival (DFS) according to BRAF and NRAS
mutational status in melanomas with unknown primary site and nodal
involvement
Molecular Features of Stage III Unknown Primary Melanoma 4321
However, the results should be interpreted with caution,
because alternative explanation of de novo development of
the tumor within lymph node experiencing a different
microenvironment from the start, resulting in aggressive
tumor behavior, is also possible.
There is no agreement on prognostic features in MUP
with nodal metastases; however, most commonly accepted
are female gender, younger age at diagnosis, and smaller
number of lymph nodes involvement.4–7 We have dem-
onstrated that MUP stage III patients have the same
important prognostic factor as known primary melanomas
with clinically detected lymph node metastases (stage IIIB,
C), e.g., nodal metastases burden expressed as number of
metastatic nodes.35
The nodal metastases in MUP patients harboring BRAF
mutation has a tendency to occur in younger age, which is
consistent with observation that p.V600E BRAF-mutated
melanomas more frequently affect younger individuals
with lower cumulative UV exposure.25,37,38 OS was not
dependent on mutational status (although a trend for poorer
prognosis in BRAF/NRAS mutated cases was visible with-
out reaching statistical significance, which may be related
to insufficient number of patients); this has been seen
previously in advanced melanomas.11,18 This study did
demonstrate that the presence of BRAF and NRAS muta-
tions had negative impact on DFS in this group of
patients.19,39
Because the manifestation of melanoma as MUP does
not alter BRAF or NRAS mutation frequency compared
with melanomas with known primary site, some other
genetic/immunological mechanism enhancing regression
must be involved.28 Based on previously published data
and our clinical data on MUP patients, supported by
mutational status of known genes involved in development
of melanoma as well as potential targets of new therapies,
we conclude that MUP has similar molecular pattern in
terms of BRAF/NRAS alterations and clinical behavior to
melanoma of known primary site of the same stage (mainly
developed in NCSD) and therefore should be managed and
treated according to the same guidelines. It has important
implications for potential adjuvant therapy as well as
treatment of metastatic disease in an era of personalized
medicine and strongly suggests that MUP with nodal
involvement should be included for clinical trials with
targeted therapy at stage III disease. BRAF and NRAS gene
mutational status does not affect patient outcome signifi-
cantly, although patients harboring mutations in those
genes have less favorable DFS.
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